标题
The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials
作者
关键词
-
出版物
Frontiers in Molecular Biosciences
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2021-03-10
DOI
10.3389/fmolb.2021.628332
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
- (2020) Yuanyuan Zhang et al. Cellular & Molecular Immunology
- Human cancers express TRAILshort, a dominant negative TRAIL splice variant, which impairs immune effector cell killing of tumor cells.
- (2020) Fatma Aboulnasr et al. CLINICAL CANCER RESEARCH
- Digital-Droplet PCR for Quantification of CD19-Directed CAR T-Cells
- (2020) Thomas Mika et al. Frontiers in Molecular Biosciences
- TNFRSF receptor-specific antibody fusion proteins with targeting controlled FcγR-independent agonistic activity
- (2019) Juliane Medler et al. Cell Death & Disease
- An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
- (2019) Steven Feins et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase 1, first-in-human study of TRAIL receptor agonist fusion protein ABBV-621.
- (2019) Mark J. Ratain et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells
- (2019) Anna Willms et al. PLoS One
- Molecular Mode of Action of TRAIL Receptor Agonists—Common Principles and Their Translational Exploitation
- (2019) Wajant Cancers
- Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox
- (2019) Lim et al. Cancers
- 457PFirst-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts
- (2019) E Calvo et al. ANNALS OF ONCOLOGY
- Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity
- (2019) Olli Dufva et al. BLOOD
- Developing TRAIL/TRAIL death receptor-based cancer therapies
- (2018) Xun Yuan et al. CANCER AND METASTASIS REVIEWS
- CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease
- (2018) Katherine C. Pehlivan et al. Current Hematologic Malignancy Reports
- Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
- (2017) Xuenong Ouyang et al. INVESTIGATIONAL NEW DRUGS
- Tumor Microenvironment and Differential Responses to Therapy
- (2017) Eishu Hirata et al. Cold Spring Harbor Perspectives in Medicine
- Cancer prevention from the perspective of global cancer burden patterns
- (2017) Hiroki Nagai et al. Journal of Thoracic Disease
- Onto better TRAILs for cancer treatment
- (2016) D de Miguel et al. CELL DEATH AND DIFFERENTIATION
- Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5
- (2016) Yuan He et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
- (2016) Djoke Hendriks et al. OncoImmunology
- The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells
- (2015) Fengtao Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Mitochondrial apoptosis: killing cancer using the enemy within
- (2015) J Lopez et al. BRITISH JOURNAL OF CANCER
- Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
- (2015) Kyriakos P. Papadopoulos et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy
- (2015) Xiaoyun Dai et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities
- (2015) Li-Qiang Pan et al. Scientific Reports
- Dulanermin with rituximab in patients with relapsed indolent B-cell lymphoma: an open-label phase 1b/2 randomised study
- (2015) Chan Yoon Cheah et al. Lancet Haematology
- A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells
- (2014) Eiji Kobayashi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- AD-O53.2—a novel recombinant fusion protein combining the activities of TRAIL/Apo2L and Smac/Diablo, overcomes resistance of human cancer cells to TRAIL/Apo2L
- (2014) Jerzy S. Pieczykolan et al. INVESTIGATIONAL NEW DRUGS
- High-level production of Fc-fused kringle domain in Pichia pastoris
- (2014) Gu Min Jeong et al. JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY
- A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†
- (2013) A. L. Cohn et al. ANNALS OF ONCOLOGY
- Death receptors as targets in cancer
- (2013) O Micheau et al. BRITISH JOURNAL OF PHARMACOLOGY
- TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer
- (2013) Charles S. Fuchs et al. CANCER
- TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
- (2013) C. Gasparini et al. CURRENT MEDICINAL CHEMISTRY
- A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer
- (2013) Martin Reck et al. LUNG CANCER
- Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer
- (2013) Andres Forero-Torres et al. Cancer Medicine
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells
- (2012) S. Surget et al. CANCER RESEARCH
- A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth
- (2012) Yuhe Qiu et al. IUBMB LIFE
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Tumor-targeted delivery of biologically active TRAIL protein
- (2010) H-Y Zhang et al. CANCER GENE THERAPY
- Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism
- (2010) Claire L. Dobson et al. mAbs
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation